Zewge Shiferaw-Deribe, MD
Endocrinology, Diabetes & Metabolism · Brooklyn, NYNPI 1508846726
Payments from drug & device makers
Across 15 payments — averaging $29.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$118
- Mannkind Corporation$96
- Sanofi-aventis U.S. LLC$66
- Medtronic$47
- Xeris Pharmaceuticals, Inc.$44
- Corcept Therapeutics$27
- plus $48 from 2 others
What the payments were for
- Food & beverage$38787%
- Gifts$5913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cequr Corporation | 2 | $118 |
| Mannkind Corporation | 3 | $96 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Medtronic | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Corcept Therapeutics | 1 | $27 |
| GSK | 1 | $25 |
| Abbott | 1 | $23 |
How this compares
$446 in reported general payments places this provider in the 35th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 146 | $163,175 |
| TrulicityDulaglutide | 111 | $130,908 |
| JardianceEmpagliflozin | 137 | $111,809 |
| FarxigaDapagliflozin Propanediol | 93 | $69,838 |
| JanuviaSitagliptin Phosphate | 82 | $59,951 |
| ProliaDenosumab | 29 | $47,338 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $29,513 |
| MounjaroTirzepatide | 17 | $23,555 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $22,883 |
| TradjentaLinagliptin | 33 | $16,820 |
| Novolog FlexpenInsulin Aspart | 65 | $13,658 |
| Bydureon BciseExenatide Microspheres | 13 | $12,358 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $6,289 |
| Cinacalcet Hcl | 13 | $4,419 |
| DapagliflozinDapagliflozin Propanediol | 12 | $4,271 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Brooklyn
- Robert SilverBrooklyn$1.3M
- Alexander PerkelvaldBrooklyn$323K
- John LeffBrooklyn$248K
- Matvey BrokhinBrooklyn$243K
- Matin SharafatkhahBrooklyn$235K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.